Trial Profile
Pomalidomide combined with Carfilzomib and Dexamethasone (PCd) for induction and consolidation followed by Pomalidomide combined with Dexamethason vs Pomalidomide maintenance for patients with Multiple Myeloma in progression after prior 1st line treatment with Lenalidomide and Bortezomib
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Sep 2023
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms EMN11HO114; HOVON 114 MM
- 11 Mar 2023 This trial has been discontinued in Austria, according to European Clinical Trials Database record.
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 22 Oct 2020 This trial is discontinued in Greece, according to European Clinical Trials Database record.